Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements

Molecular Carcinogenesis

Volumn 48, Issue 10, 2009, Pages 895-902

  Kouidou, Sofia ^a   Malousi, Andigoni ^a   Maglaveras, Nicos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Carcinogenesis; Exonic splicing enhancers; Li Fraumeni; Methylation; Splicing

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DNA METHYLATION; DNA SPLICING; FAMILIAL CANCER; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SPLICING DEFECT; TUMOR SUPPRESSOR GENE; CODON; CPG ISLAND; ENHANCER REGION; EXON; GENETICS; MUTATION; REGULATORY SEQUENCE; RNA SPLICING; SYNDROME;

CODON; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; ENHANCER ELEMENTS, GENETIC; EXONS; HUMANS; LI-FRAUMENI SYNDROME; MUTATION; REGULATORY SEQUENCES, NUCLEIC ACID; RNA SPLICING; SYNDROME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349952369     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20537     Document Type: Article

References (28)

1. Toledo F, Wahl GM. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-923.
2. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 1997;71:79-87. (Pubitemid 27158413)
3. Avigad S, Barel D, Blau O, et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997;14:1541-1545. (Pubitemid 27182836)
4. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995;56:608-615.
5. Varley JM, McGown G, Thorncroft M, et al. A novel TP53 splicing mutation in a Li-Fraumeni syndrome family: A patient with Wilms' tumour is not a mutation carrier. Br J Cancer 1998;78:1081-1083. (Pubitemid 28463986)
6. Varley JM, Chapman P, McGown G, et al. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene 1998;16:3291-3298. (Pubitemid 28330428)
7. Varley JM, Attwooll C, White G, et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001;20:2647-2654. (Pubitemid 32525295)
8. Verselis SJ, Rheinwald JG, Fraumeni JF, Li FP. Novel p53 splice site mutations in three families with Li-Fraumeni syndrome. Oncogene 2000;19:4230-4235.
9. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-2137. (Pubitemid 41330315)
10. Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17. (Pubitemid 40075908)
11. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629. (Pubitemid 46744292)
12. Kouidou S, Malousi A, Kyventidis A, Fragou A, Maglaveras N. G:C>A:T mutations and epigenetic regulation of p53 in breast cancer. Breast Cancer Res Treat 2007;106:351-360.
13. Wright JD, Lim C. Mechanism of DNA-binding loss upon single-point mutation in p53. J Biosci 2007;32:827-839. (Pubitemid 47435515)
14. Ang HC, Joerger AC, Mayer S, Fersht AR. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem 2006;281:21934-21941. (Pubitemid 44181897)
15. Lamolle G, Marin M, varez-Valin F. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res 2006;600:102-112.
16. Kouidou S, Malousi A, Maglaveras N. Methylation and repeats in silent and nonsense mutations of p53. Mutat Res 2006;599:167-177.
17. Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene 1995;10:1493-1499.
18. Young JI, Hong EP, Castle JC, et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci USA 2005;102:17551-17558.
19. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
20. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-3571. (Pubitemid 37442199)
21. Huang HY, Chien CH, Jen KH, Huang HD. RegRNA: An integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res 2006;34:W429-W434.
22. Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: Sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987; 15:7155-7174.
23. Wang Z, Xiao X, Van NE, Burge CB. General and specific functions of exonic splicing silencers in splicing control. Mol Cell 2006;23:61-70. (Pubitemid 43963442)
24. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther 2009;16:1-12.
25. Soussi T, Asselain B, Hamroun D, et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 2006;12:62-69. (Pubitemid 43166177)
26. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer 2007;97:277-282.
27. Baumbusch LO, Myhre S, Langerod A, et al. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer 2006;5:47. (Pubitemid 44822928)
28. Pekova S, Cmejla R, Smolej L, et al. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leuk Res 2008; 32:395-400. (Pubitemid 351295913)